维多利亚老品牌76696vic-在线入口

Be the most trusted biotech company

2023-10-24

Results From the Preclinical Study of HLX43, a Potential FIC PD-L1-Targeting ADC Released at 2023 ESMO
2023-10-24

Results From the Preclinical Study of HLX42, a Potential BIC EGFR-Targeting ADC Released at 2023 ESMO
2023-10-20

Henlius Xuhui Facility Passes PIC/S Member ANVISA GMP Inspection for HANLIKANG and HANQUYOU
2023-10-12

Henlius Will be at CPHI Barcelona 2023
2023-10-11

Henlius Xuhui Facility Passes GMP Inspection for HANSIZHUANG by PIC/S Member BPOM
2023-09-22

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
2023-09-21

Henlius to Release the Preclinical Profiles of 2 ADC Programs at ESMO Congress 2023
2023-09-12

Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA
2023-09-11

The Phase 3 Clinical Study Results of a Novel Anti-PD-1 mAb HANSIZHUANG for the First-Line Treatment of sqNSCLC Released at WCLC 2023